Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

RAFI , NSA , NIXT
Sort by: Date|Relevance

Biopharma's Early Data Show Immunotherapy's Efficacy in Ovarian Cancer

The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report. In a March 26 research note, analyst Joseph Pantginis reported that IMV Inc.'s (IMV:TSX; IMMVD:OTCQX) preliminary monotherapy data confirmed the efficacy o...
Streetwise Reports | April 1, 2019 |

California-Based Biopharma Signs Licensing Deal for Acquired Asset

The transaction details and the drug platform's potential are addressed in an H.C. Wainwright & Co. report. In May 21 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Ligand Pharmaceuticals Inc. (LGND:NASDAQ) signed a licensing d...
Streetwise Reports | May 27, 2019 |

New Data Could Drive Use of Pancreatic Cancer Early Detection Test

The recent results and their implications are provided in an H.C. Wainwright & Co. report. In an Oct. 25 research note, H.C. Wainwright & Co. analyst Yi Chen reported that newly compiled data support the clinical utility of Interpace Diagnostics Group Inc.'s (IDXG:NA...
Streetwise Reports | October 30, 2019 |

Biopharma to Test Immunity Activator in Advanced Solid Cancers

The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. In a Dec. 12 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) plans to ...
Streetwise Reports | December 19, 2019 |

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. In a Dec. 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) launched its pivotal trial program for...
Streetwise Reports | January 6, 2020 |

Two Stock-Moving Catalysts Expected in March for Biopharma

These events for Axsome Therapeutics are described in an H.C. Wainwright & Co. report. In a Feb. 24 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Axsome Therapeutics Inc. (AXSM:NASDAQ) finished patient enrollment for its INTERCEP...
Streetwise Reports | February 26, 2020 |

Biopharma to Accelerate Alzheimer Trial Completion

The upcoming catalysts for Axsome Therapeutics and the effects of COVID-19 on its clinical activities are discussed in an H.C. Wainwright & Co. report. In a March 20 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Axsome Therapeutics Inc. ...
Streetwise Reports | March 26, 2020 |

California Biotech Partners for Manufacture of COVID-19 Vaccine Candidate

Arcturus Therapeutics Holdings' arrangement is explained and commented on in an H.C. Wainwright & Co. report. In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnersh...
Streetwise Reports | May 7, 2020 |

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'

An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. In a March 18 research note, H.C. Wainwright & Co. analyst Andrew Fein purported that Constellation Pharmaceuticals Inc.'s (CNST:NASDAQ) "strong and balanced pi...
Streetwise Reports | March 25, 2019 |

San Diego Biopharma Features 'Strong and Balanced Pipeline'

An H.C. Wainwright & Co. report discussed what sets this company's asset apart from similar products. In a March 21 research note, H.C. Wainwright & Co. analyst Andrew Fein wrote that MEI Pharma Inc.'s (MEIP:NASDAQ) oral PK3K delta inhibitor, ME-401, differentiates it...
Streetwise Reports | March 28, 2019 |
1 2 3 4 5 6 7 8 9 10 ...